A股重磅！科创成长层，要上新！

Core Viewpoint - He Yuan Bio is set to become a new member of the Sci-Tech Innovation Board as it officially starts its issuance process, marking a significant step in the "1+6" reform of the Sci-Tech Board [2][4]. Group 1: Company Overview - Wuhan He Yuan Bio Technology Co., Ltd. is the first company to initiate the issuance process after the re-launch of the fifth set of standards for the Sci-Tech Board [6]. - He Yuan Bio has developed a globally pioneering "rice-derived hematopoietic" technology, which has received support from the national "Major New Drug Creation" program [6]. - The company's innovative drug, recombinant human albumin injection (from rice), was approved for market release by the National Medical Products Administration in July, aiming to reduce China's reliance on imported human serum albumin [6]. Group 2: Market Context - The issuance of He Yuan Bio is a reflection of the policy direction to enhance the adaptability and inclusiveness of the Sci-Tech Board for high-quality technology enterprises [6]. - Since the announcement of the "1+6" reform policy in June, the Sci-Tech Board has received 15 new IPO applications, including four from unprofitable companies [9]. - The Shanghai Stock Exchange has completed the technical system testing for the new registration of the Sci-Tech Growth Layer, with 5 million investors already authorized to trade in this layer [10]. Group 3: Issuance Details - He Yuan Bio is the first company to adopt differentiated lock-up and allocation arrangements for offline issuance, with a minimum lock-up ratio of 40% for offline investors [6]. - The company has set three tiers of differentiated lock-up levels for investor bids, with the highest lock-up tier having a distribution ratio at least nine times that of the lowest tier [6][7]. - The recent revision of the issuance and underwriting rules by the Shanghai Stock Exchange allows unprofitable companies to adopt agreed lock-up methods, encouraging professional institutions to play a larger role in new stock pricing [7].